Cargando…

The optimal dose of mobilisation therapy in the ICU: a prospective cohort study

BACKGROUND: This study aimed to assess the impact of duration of early mobilisation on survivors of critical illness. The hypothesis was that interventions lasting over 40 min, as per the German guideline, positively affect the functional status at ICU discharge. METHODS: Prospective single-centre c...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenz, Marco, Fuest, Kristina, Ulm, Bernhard, Grunow, Julius J., Warner, Linus, Bald, Annika, Arsene, Vanessa, Verfuß, Michael, Daum, Nils, Blobner, Manfred, Schaller, Stefan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658796/
https://www.ncbi.nlm.nih.gov/pubmed/37986100
http://dx.doi.org/10.1186/s40560-023-00703-1
_version_ 1785148242733826048
author Lorenz, Marco
Fuest, Kristina
Ulm, Bernhard
Grunow, Julius J.
Warner, Linus
Bald, Annika
Arsene, Vanessa
Verfuß, Michael
Daum, Nils
Blobner, Manfred
Schaller, Stefan J.
author_facet Lorenz, Marco
Fuest, Kristina
Ulm, Bernhard
Grunow, Julius J.
Warner, Linus
Bald, Annika
Arsene, Vanessa
Verfuß, Michael
Daum, Nils
Blobner, Manfred
Schaller, Stefan J.
author_sort Lorenz, Marco
collection PubMed
description BACKGROUND: This study aimed to assess the impact of duration of early mobilisation on survivors of critical illness. The hypothesis was that interventions lasting over 40 min, as per the German guideline, positively affect the functional status at ICU discharge. METHODS: Prospective single-centre cohort study conducted in two ICUs in Germany. In 684 critically ill patients surviving an ICU stay > 24 h, out-of-bed mobilisation of more than 40 min was evaluated. RESULTS: Daily mobilisation ≥ 40 min was identified as an independent predictor of an improved functional status upon ICU discharge. This effect on the primary outcome measure, change of Mobility-Barthel until ICU discharge, was observed in three different models for baseline patient characteristics (average treatment effect (ATE), all three models p < 0.001). When mobilisation parameters like level of mobilisation, were included in the analysis, the average treatment effect disappeared [ATE 1.0 (95% CI − 0.4 to 2.4), p = 0.16]. CONCLUSIONS: A mobilisation duration of more than 40 min positively impacts functional outcomes at ICU discharge. However, the maximum level achieved during ICU stay was the most crucial factor regarding adequate dosage, as higher duration did not show an additional benefit in patients with already high mobilisation levels. Trial registration: Prospective Registry of Mobilization-, Routine- and Outcome Data of Intensive Care Patients (MOBDB), NCT03666286. Registered 11 September 2018—retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT03666286. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40560-023-00703-1.
format Online
Article
Text
id pubmed-10658796
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106587962023-11-20 The optimal dose of mobilisation therapy in the ICU: a prospective cohort study Lorenz, Marco Fuest, Kristina Ulm, Bernhard Grunow, Julius J. Warner, Linus Bald, Annika Arsene, Vanessa Verfuß, Michael Daum, Nils Blobner, Manfred Schaller, Stefan J. J Intensive Care Research BACKGROUND: This study aimed to assess the impact of duration of early mobilisation on survivors of critical illness. The hypothesis was that interventions lasting over 40 min, as per the German guideline, positively affect the functional status at ICU discharge. METHODS: Prospective single-centre cohort study conducted in two ICUs in Germany. In 684 critically ill patients surviving an ICU stay > 24 h, out-of-bed mobilisation of more than 40 min was evaluated. RESULTS: Daily mobilisation ≥ 40 min was identified as an independent predictor of an improved functional status upon ICU discharge. This effect on the primary outcome measure, change of Mobility-Barthel until ICU discharge, was observed in three different models for baseline patient characteristics (average treatment effect (ATE), all three models p < 0.001). When mobilisation parameters like level of mobilisation, were included in the analysis, the average treatment effect disappeared [ATE 1.0 (95% CI − 0.4 to 2.4), p = 0.16]. CONCLUSIONS: A mobilisation duration of more than 40 min positively impacts functional outcomes at ICU discharge. However, the maximum level achieved during ICU stay was the most crucial factor regarding adequate dosage, as higher duration did not show an additional benefit in patients with already high mobilisation levels. Trial registration: Prospective Registry of Mobilization-, Routine- and Outcome Data of Intensive Care Patients (MOBDB), NCT03666286. Registered 11 September 2018—retrospectively registered, https://classic.clinicaltrials.gov/ct2/show/NCT03666286. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40560-023-00703-1. BioMed Central 2023-11-20 /pmc/articles/PMC10658796/ /pubmed/37986100 http://dx.doi.org/10.1186/s40560-023-00703-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lorenz, Marco
Fuest, Kristina
Ulm, Bernhard
Grunow, Julius J.
Warner, Linus
Bald, Annika
Arsene, Vanessa
Verfuß, Michael
Daum, Nils
Blobner, Manfred
Schaller, Stefan J.
The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title_full The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title_fullStr The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title_full_unstemmed The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title_short The optimal dose of mobilisation therapy in the ICU: a prospective cohort study
title_sort optimal dose of mobilisation therapy in the icu: a prospective cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658796/
https://www.ncbi.nlm.nih.gov/pubmed/37986100
http://dx.doi.org/10.1186/s40560-023-00703-1
work_keys_str_mv AT lorenzmarco theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT fuestkristina theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT ulmbernhard theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT grunowjuliusj theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT warnerlinus theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT baldannika theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT arsenevanessa theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT verfußmichael theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT daumnils theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT blobnermanfred theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT schallerstefanj theoptimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT lorenzmarco optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT fuestkristina optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT ulmbernhard optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT grunowjuliusj optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT warnerlinus optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT baldannika optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT arsenevanessa optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT verfußmichael optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT daumnils optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT blobnermanfred optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy
AT schallerstefanj optimaldoseofmobilisationtherapyintheicuaprospectivecohortstudy